Carlson Capital’s Biogen BIIB Stock Holding History

Carlson Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$1.38M	–	111
2022 Q4	$1.38M	Buy	5,000 +2,500	+100%	+$706K	0.11%	99
2022 Q3	$668K	Buy	+2,500	New	+$531K	0.05%	111
2017 Q2	–	Sell	-144,895	Closed	-$39.6M	–	256
2017 Q1	$39.6M	Sell	144,895 -40,357	-22%	-$11.4M	0.5%	61
2016 Q4	$52.5M	Buy	185,252 +166,852	+907%	+$49.5M	0.63%	46
2016 Q3	$5.76M	Sell	18,400 -24,335	-57%	-$7.21M	0.07%	211
2016 Q2	$10.3M	Buy	+42,735	New	+$11.3M	0.13%	195
2016 Q1	–	Sell	-44,048	Closed	-$13.5M	–	284
2015 Q4	$13.5M	Buy	+44,048	New	+$12.7M	0.15%	174
2015 Q3	–	Sell	-51,620	Closed	-$20.9M	–	308
2015 Q2	$20.9M	Buy	51,620 +11,320	+28%	+$4.54M	0.23%	141
2015 Q1	$17M	Buy	40,300 +12,780	+46%	+$5.04M	0.19%	161
2014 Q4	$9.34M	Buy	+27,520	New	+$8.9M	0.09%	239

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Carlson Capital's BIIB Position: Q1 2023 in Review

Carlson Capital sold out of Biogen (BIIB) in Q1 2023, closing a stake of 5,000 shares — an estimated $1.38M sold.

Carlson Capital first reported a position in BIIB in Q4 2014 and held it in 10 quarters. The position peaked at $52.5M in Q4 2016. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Carlson Capital reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
Carlson Capital sold 5,000 Biogen shares in Q1 2023, an estimated $1.38M.
Carlson Capital first reported a position in Biogen in Q4 2014 and held it in 10 quarters.
Carlson Capital's Biogen position peaked at $52.5M in Q4 2016.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Carlson Capital's 13F filing for Q1 2023, filed 12 May 2023.